A 64-year-old male patient diagnosed with B-cell lymphoma required regular platelet transfusions due to persistent thrombocytopenia. Over time, he developed severe transfusion-related allergic reactions, including anaphylaxis, necessitating the use of washed apheresis platelets (W-APLT). However, as the designated blood center was unable to produce W-APLT, the issue was resolved by collaborating with a neighboring blood center to source the product.Key strategies included verifying the patient’s history of transfusion-related anaphylaxis, coordinating the production schedule of blood products, and implementing administrative procedures such as pre-scheduled ambulance transport on the day of transfusion. These measures ensured the timely supply of W-APLT while minimizing the risk of product wastage. As a result, the patient successfully received multiple W-APLT transfusions without further allergic reactions. This case serves as a model for overcoming infrastructure limitations in W-APLT supply through hospital-blood center collaboration, to provide timely and safe blood products to patients at risk of severe transfusion-related allergic reactions and anaphylaxis.

A 64-year-old male patient diagnosed with B-cell lymphoma required regular platelet transfusions due to persistent thrombocytopenia. Over time, he developed severe transfusion-related allergic reactions, including anaphylaxis, necessitating the use of washed apheresis platelets (W-APLT). However, as the designated blood center was unable to produce W-APLT, the issue was resolved by collaborating with a neighboring blood center to source the product.Key strategies included verifying the patient’s history of transfusion-related anaphylaxis, coordinating the production schedule of blood products, and implementing administrative procedures such as pre-scheduled ambulance transport on the day of transfusion. These measures ensured the timely supply of W-APLT while minimizing the risk of product wastage. As a result, the patient successfully received multiple W-APLT transfusions without further allergic reactions. This case serves as a model for overcoming infrastructure limitations in W-APLT supply through hospital-blood center collaboration, to provide timely and safe blood products to patients at risk of severe transfusion-related allergic reactions and anaphylaxis.

A 64-year-old male patient diagnosed with B-cell lymphoma required regular platelet transfusions due to persistent thrombocytopenia. Over time, he developed severe transfusion-related allergic reactions, including anaphylaxis, necessitating the use of washed apheresis platelets (W-APLT). However, as the designated blood center was unable to produce W-APLT, the issue was resolved by collaborating with a neighboring blood center to source the product.Key strategies included verifying the patient’s history of transfusion-related anaphylaxis, coordinating the production schedule of blood products, and implementing administrative procedures such as pre-scheduled ambulance transport on the day of transfusion. These measures ensured the timely supply of W-APLT while minimizing the risk of product wastage. As a result, the patient successfully received multiple W-APLT transfusions without further allergic reactions. This case serves as a model for overcoming infrastructure limitations in W-APLT supply through hospital-blood center collaboration, to provide timely and safe blood products to patients at risk of severe transfusion-related allergic reactions and anaphylaxis.

A 64-year-old male patient diagnosed with B-cell lymphoma required regular platelet transfusions due to persistent thrombocytopenia. Over time, he developed severe transfusion-related allergic reactions, including anaphylaxis, necessitating the use of washed apheresis platelets (W-APLT). However, as the designated blood center was unable to produce W-APLT, the issue was resolved by collaborating with a neighboring blood center to source the product.Key strategies included verifying the patient’s history of transfusion-related anaphylaxis, coordinating the production schedule of blood products, and implementing administrative procedures such as pre-scheduled ambulance transport on the day of transfusion. These measures ensured the timely supply of W-APLT while minimizing the risk of product wastage. As a result, the patient successfully received multiple W-APLT transfusions without further allergic reactions. This case serves as a model for overcoming infrastructure limitations in W-APLT supply through hospital-blood center collaboration, to provide timely and safe blood products to patients at risk of severe transfusion-related allergic reactions and anaphylaxis.

Syringocystadenoma papilliferum (SCAP) and apocrine hidrocystoma (AH) are benign apocrine neoplasms that usually occur separately. SCAP arises predominantly in head and neck, while AH typically develop in periorbital area. We report a case of a 68-year-old male with an asymptomatic erythematous papulonodule that occurred on his back 3 years ago. Histologic examination showed cystic invagination extending from the epidermis into the dermis with some papillary projections. The invaginated portion was lined by epithelial bilayer composed of cuboidal and columnar cells, and decapitation secretion was observed in the inner epithelial layer. In the deep dermis, multiple cystic spaces with variable sizes were observed, and these cysts also presented double layers of the epithelium and decapitation secretion.According to such histologic features, the coexistence of SCAP and AH within a single lesion was demonstrated. The patient was recommended to completely remove the remaining lesion after punch biopsy, but he refused further surgical management. Herein, we report an unusual case of complex apocrine tumor with a rare composition in an atypical site.

The areola is a rare location for squamous cell carcinoma (SCC) because sunlight exposure, the main risk factor for SCC, is unusual on it. Acantholytic SCC (ASCC) is a rare histologic variant of SCC, characterized by pseudoglandular appearance with acantholytic tumor cells. A 59-year-old male presented a painful erythematous papule on his right areola. He had a history of psoralen ultraviolet A phototherapy for psoriasis in his 20s. Biopsy revealed an epithelial tumor and pseudoglandular structures with acantholytic tumor cells. In immunohistochemistry, cytokeratin 5/6, epithelial membrane antigen, and p63 were positive, while cytokeratin 7, carcinoembryonic antigen, S-100, and estrogen and progesterone receptors were negative. Periodic acid-Schiff stain was negative. Ki-67 labeling index was 79.7%. The final diagnosis was ASCC of the areola. After wide local excision, recurrence have not been reported. Here, we report a case of ASCC on the areola, focusing on its rare histologic variant and uncommon location.

Background: Guselkumab is a monoclonal antibody that selectively blocks the p19 subunit of interleukin-23. It has shown good efficacy and safety profile in several clinical trials of plaque psoriasis. However, studies on the efficacy of guselkumab in patients treated with other biologics are lacking. Objective: We aimed to investigate the efficacy and safety profile of guselkumab in patients with moderate-to-severe plaque psoriasis. We also compared the efficacy of guselkumab between biologic-naïve (Bio-Naïve) and biologicexperienced (Bio-Ex) patients. Methods: This multicenter, retrospective study included 72 patients treated with guselkumab. The patients’ clinical characteristics and psoriasis area and severity index (PASI) scores were recorded at each visit. The PASI90 and PASI100 responses and mean PASI scores were compared between the Bio-Naïve and Bio-Ex groups. Results: Fifty-five Bio-Naïve patients and 17 Bio-Ex patients were included in the study. At week 20, there were no significant differences in the PASI90 (64.2% vs. 53.8%) and PASI100 (28.3% vs. 15.4%) responses between the groups. However, at weeks 36 and 44, the PASI90 response (week 36: 89.2% vs. 36.4% and week 44: 97.8% vs. 63.6%) and the PASI100 response (week 36: 64.9% vs. 18.2% and week 44: 68.9% vs. 27.3%) were significantly higher in the Bio-Naïve group (p＜0.05). There were no differences in PASI90 and PASI100 responses between the groups in terms of other clinical characteristics and comorbidities at week 20. Conclusion The efficacy of guselkumab remained consistent among patients in whom other biologics had failed. However, the efficacy was slightly lower in the Bio-Ex group than in the Bio-Naïve group.

Background: Although the older adult population in Korea is growing, few studies have investigated the profile of late-onset vitiligo (onset at 50 years of age or above) to date. Objective: The present study aimed to describe the clinical characteristics and course of patients with late-onset vitiligo in Korea. Methods: The present single-center retrospective study included 132 patients with late-onset vitiligo from January 1, 2009 to November 30, 2022. We analyzed patient demographics and vitiligo characteristics. Further, we evaluated the progress of late-onset vitiligo using the Vitiligo Area Severity Index (VASI) score. Results: The study included more females (n=83, 62.9%) than males (n=49, 37.1%), with an average age of onset 60.9±7.4 years. The average duration of the disease before presentation was 15.0±27.3 months. A family history of vitiligo was identified in eight patients (6.1%), and seven patients (5.3%) had associated autoimmune diseases.Acrofacial vitiligo was the most common type (n=56, 43.1%), and the head and neck area were the commonly affected site at disease onset (n=93, 70.5%). The Koebner phenomenon was observed in seven patients (5.3%), and chemical-induced vitiligo was suspected in three patients (2.3%). Treatment was administered to 131 patients (99.2%). The VASI score decreased in 93 patients (83.0%), with an average decline rate of 58.56%. Conclusion Late-onset vitiligo tends to be of the acrofacial vitiligo subtype in the Korean population. Patients demonstrated a strong desire to treat vitiligo, and treatment response was promising. Further larger-scale studies to elucidate the characteristics and progression of late-onset vitiligo may be needed.

Trigeminal trophic syndrome (TTS) is a rare condition characterized by anesthesia, paresthesia, and facial ulceration involving the trigeminal dermatome secondary to self-manipulation of the skin after a peripheral or central injury to the trigeminal nerve or its branches. Differential diagnosis of TTS includes conditions presenting with chronic facial ulceration, such as various infectious diseases, malignancy, vasculitis, pyoderma gangrenosum and dermatitis artefacta. We report a case of postherpetic TTS and highlight the importance of early diagnosis and prompt treatment of this condition, which may commonly be misdiagnosed.